Evaluation of a new score associated with acute kidney injury in patients treated with cisplatin based EXTREME regimen.

Background: This study evaluates the association of diuresis and hydration through a new monitoring indicator called and the risk of acute kidney injury in patients treated with cisplatin based-EXTREME regimen.

Methods: We retrospectively reviewed all the cycles of patients with recurrent and/or metastatic head and neck cancer who received cisplatin based-EXTREME regimen from June 2008 to July 2022. Hydration regimen, urine output and concomitant treatments data were collected on the day of cisplatin infusion and the following day of each course received.